Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Specifically March 2, 2026)
Context: The filing serves to incorporate a press release regarding a new independent study published in the journal PLOS One. The study evaluates the safety and efficacy of the company's ProSense® Cryoablation system for the treatment of breast fibroadenomas.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on clinical developments rather than a periodic financial statement.
Material Changes
No financial material changes versus the prior comparable period are reported in this document. The material update is the publication of clinical data demonstrating the safety and effectiveness of the ProSense® Cryoablation system for breast fibroadenomas.
Guidance, Outlook, and Risks
Management Commentary: The company highlights the independent study as evidence supporting the clinical utility of its technology for a specific indication (breast fibroadenomas).
Outlook: The filing does not contain specific financial guidance or revenue projections.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard incorporation by reference into registration statements.
Investor Verification Checklist
- Verify the full text of the independent study published in PLOS One referenced in Exhibit 99.1.
- Confirm the specific clinical endpoints and patient sample size used in the ProSense® Cryoablation study for breast fibroadenomas.
- Review the company's latest Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.
- Assess the regulatory pathway required to expand the ProSense® indication based on this new data.